TIDMONC
RNS Number : 4610C
Oncimmune Holdings PLC
19 October 2020
19 October 2020
This announcement corrects the The Investor Meet Company link to
the live presentation of the results on Friday, 30 October at 15:00
GMT.
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Replacement Notice of Full Year Results ended 31 May 2020
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, will be announcing its full year results
for the year ended 31 May 2020 on Friday, 30 October 2020.
Adam Hill, Chief Executive Officer, together with Matthew Hall,
Chief Financial Officer, will host a presentation and conference
call for analysts at 11:30am GMT on the day of the results.
For conference call details please contact Alexander Davis of
FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727
1000.
The management team will also host on Investor Meet Company a
live presentation of the results on Friday, 30 October at 15:00
GMT.
-- The online presentation will be open to all existing
shareholders and potential new investors.
-- Questions can be submitted before the event via your Investor
Meet Company dashboard or at any time during the live presentation
via the "Ask a Question" function. Responses to the Q&A will be
published at the earliest opportunity on the Investor Meet Company
platform.
-- Investor feedback can also be submitted directly to
management immediately following the event.
Access to Investor Meet Company is free and interested parties
can register to attend the presentation via the following link:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Attendees who have already registered on the Investor Meet
Company platform to meet the Company will automatically receive an
invitation to the presentation.
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our
passion to improve cancer survival and give people extra time.
Oncimmune's immunodiagnostic test, EarlyCDT(R) , can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis.
The unique combination of our core technology and understanding
of the immune system, powers our ImmunoINSIGHTS service; a
proprietary platform that enables life science organisations to
optimise drug development and delivery, leading to more effective,
targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform
diagnostic technology in 2009, followed by the launch of its first
commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over
200,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised
controlled trial for the early detection of lung cancer using
biomarkers, the successful National Health Service (NHS) Early
detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk
smokers in Scotland. This trial demonstrated that EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
Oncimmune joined the AIM Market of the London Stock Exchange in May
2016 under the ticker ONC.L
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORMLBRTMTBBMPM
(END) Dow Jones Newswires
October 19, 2020 03:21 ET (07:21 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024